Vivesto AB
Closed
0
Overview
Share price change
24h
Min
Max
Income | -1.9M -9.1M |
|---|---|
EPS | -0.015 |
Employees | 4 |
EBITDA | -1.8M -8.9M |
Next Earnings | 13 Aug 2026 |
|---|
Market Cap | 42M 93M |
|---|---|
Previous open | 0 |
Previous close | 0 |
Vivesto AB Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Vivesto AB Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Vivesto AB
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
